Scientific Review Committee
The Scientific Review Committee (SRC), co-chaired by Dr. Geoffrey Gibney (DC) and Dr. Martin Gutierrez (NJ), is a multidisciplinary standing committee that provides peer review of cancer-related clinical research protocols using Georgetown Lombardi resources for scientific merit and ensures the prioritization of protocols based on scientific priorities and subject availability.
The SRC consists of Lombardi DC and NJ faculty and staff with the necessary level of expertise within each respective scientific research area. The SRC does not duplicate the scientific peer review of protocols approved through NIH-funded mechanisms and other approved peer-review agencies. All cancer-related clinical research studies must receive PRMC approval prior to activation.
To contact the SRC, please email LombardiSRC@georgetown.edu.
2023 SRC Schedule
Full SRC committee meetings occur monthly on the Xth Wednesday. The deadline for submission of protocols to the regulatory team member is two weeks prior to the meeting date. The regulatory team member will submit the protocols via OnCore at least one week prior to the meeting date.
New Protocol Submissions
The SRC reviews all cancer-related clinical studies for Georgetown Lombardi, aside from observational and epidemiologic studies dealing with healthy human subjects and the population sciences which are exempt per NCI guidelines. The SRC also conducts a bi-annual review of open protocols to monitor accrual and progress, recommending the modification or closure of underperforming studies as per the Scientific Progress Review Committee (SPRC) guidelines.
Download the Disease Group Priority Rubric
Download the Disease Group Cover Letter
Scientific Progress Review Committee (SPRC)
The Scientific Progress Review Committee (SPRC) is a subcommittee of the PRMC. The SPRC is chaired by Dr. Stephen Liu, Lombardi’s DG Lead for Thoracic Oncology. The SPRC reviews all NCI reportable cancer-related research studies open to accrual across the consortium twice yearly in order to monitor continued scientific relevance and accrual progress of the studies and to recommend modification or closure of underperforming studies to the PRMC.